Natera touts positive results for Merkel cell carcinoma surveillance test

Natera has unveiled data that shows the efficacy of its molecular residual disease (MRD) test in detecting Merkel cell carcinoma, a type of aggressive skin cancer.

The results, published in the Journal of Clinical Oncology, demonstrated that the test – named Signatera – had a sensitivity of around 95%. This measures how well a test can identify tumour cells at the time of enrollment.